Common Reasons and Causes for Not Getting Pregnant: Evidence-Based Insights from Reproductive Health Specialists

Difficulty conceiving affects approximately 12% of women aged 15–44 in the United States, according to the CDC’s 2023 National Survey of Family Growth. Among heterosexual couples trying to conceive for at least 12 months without success, roughly 1 in 8 experiences infertility—a condition defined by the American Society for Reproductive Medicine (ASRM) as the inability to achieve pregnancy after 12 months of regular, unprotected intercourse (or 6 months if the woman is over age 35). This article presents evidence-based causes—not speculation or myth—drawing on clinical guidelines from ASRM, the World Health Organization, and peer-reviewed studies published in journals like Fertility and Sterility and Human Reproduction. We detail hormonal, anatomical, genetic, and behavioral contributors with precise prevalence rates, diagnostic thresholds, and measurable benchmarks—including follicle-stimulating hormone (FSH) levels above 15 mIU/mL indicating diminished ovarian reserve, or semen analyses showing sperm concentration below 15 million/mL per WHO 2021 criteria.

Hormonal Imbalances and Ovulatory Dysfunction

Ovulatory disorders account for about 25–30% of all infertility cases, making them the single largest contributor to female-factor infertility. Polycystic ovary syndrome (PCOS) alone affects an estimated 6–12% of reproductive-age women globally—roughly 5 million people in the U.S., per NIH data. PCOS is diagnosed using the Rotterdam Criteria, requiring at least two of: (1) oligo- or anovulation, (2) clinical or biochemical signs of hyperandrogenism (e.g., serum testosterone > 0.5 ng/mL), and (3) polycystic ovaries on transvaginal ultrasound (≥20 follicles measuring 2–9 mm per ovary or ovarian volume >10 mL).

Thyroid Disorders and Prolactin Dysregulation

Subclinical and overt thyroid disease significantly disrupt gonadotropin-releasing hormone (GnRH) pulsatility. A 2022 meta-analysis in The Journal of Clinical Endocrinology & Metabolism found that women with TSH >2.5 mIU/L had a 42% lower probability of conception within six cycles compared to those with TSH <1.2 mIU/L. Similarly, hyperprolactinemia—often caused by microadenomas (<10 mm) in the anterior pituitary—suppresses dopamine inhibition of prolactin secretion. Serum prolactin above 25 ng/mL (measured via Roche Cobas e602 immunoassay) correlates strongly with anovulation. Bromocriptine and cabergoline remain first-line treatments, with cabergoline achieving normalization in 85% of patients within 8 weeks at doses of 0.25–0.5 mg twice weekly.

Diminished Ovarian Reserve and Age-Related Decline

Ovarian reserve declines predictably with age. Anti-Müllerian hormone (AMH) is a key biomarker: median AMH drops from 3.0 ng/mL at age 25 to 1.1 ng/mL at age 35 and 0.2 ng/mL at age 40 (data from the Boston IVF Longitudinal Study, n=12,437). FSH measured on cycle day 3 is another validated marker; values ≥10 mIU/mL indicate reduced responsiveness to stimulation, while ≥15 mIU/mL suggest poor prognosis for natural conception. Importantly, chronological age remains the strongest predictor of live birth rate—even among women with normal AMH: live birth rates per IVF cycle fall from 41.2% (ages 30–34) to 11.7% (ages 40–42), per 2023 SART Clinic Outcome Reporting System data.

Male Factor Infertility: Beyond Sperm Count

Male factors contribute to infertility in approximately 40–50% of couples—and are the sole cause in 20–30%. The WHO’s fifth edition laboratory manual (2021) established updated reference limits based on data from 4,500 fertile men: normal semen parameters now include volume ≥1.4 mL, total sperm count ≥39 million per ejaculate, concentration ≥15 million/mL, motility ≥40% progressive or total motile, and morphology ≥4% normal forms (strict Kruger criteria). These thresholds reflect rigorous statistical analysis—not arbitrary cutoffs.

Varicocele and Oxidative Stress Damage

Varicoceles—dilated pampiniform plexus veins affecting ~15% of adolescent and adult males—are present in up to 35% of infertile men. Left-sided varicoceles predominate (90%), and grade III (palpable at rest, visible) correlate with mean reductions in total motile sperm count of 42%, per a 2021 randomized trial in Urology. More critically, varicoceles elevate scrotal temperature by 0.6–1.2°C (measured with Fluke TiX580 thermal imaging), increasing reactive oxygen species (ROS) production. Seminal ROS levels >1.3 × 10⁶ counts per minute per 20 million sperm (assayed via chemiluminescence with Luminol reagent) impair DNA integrity—shown in studies using SCSA (Sperm Chromatin Structure Assay) to reveal DNA fragmentation index (DFI) >30% in affected men.

Genetic and Structural Abnormalities

Klinefelter syndrome (47,XXY) occurs in 1 in 500–1,000 male births and accounts for ~11% of nonobstructive azoospermia cases. Y-chromosome microdeletions—particularly in the AZF region—appear in 5–10% of men with sperm concentrations <1 million/mL. Diagnostic testing uses PCR amplification of sequence-tagged sites (STSs) like sY84 and sY127 (per EAA/EMQN guidelines). Congenital bilateral absence of the vas deferens (CBAVD), seen in 98% of men with cystic fibrosis (CFTR gene mutations), results in obstructive azoospermia despite normal testicular sperm production. Over 2,000 CFTR variants are cataloged; the F508del mutation alone accounts for 70% of CF alleles in North America.

Anatomical and Tubal Factors

Tubal factor infertility contributes to 25–35% of female infertility cases. Hydrosalpinx—fluid-filled, dilated fallopian tubes—reduces IVF success by 50% due to embryotoxic fluid reflux, per Cochrane Review 2022. Laparoscopic salpingectomy prior to IVF improves live birth rates from 22% to 33% (RR 1.51, 95% CI 1.22–1.87).

Endometriosis and Adhesions

Endometriosis affects ~10% of reproductive-age women but is present in 25–50% of infertile women. The revised ASRM classification (rASRM) stages I–IV do not reliably predict fertility outcomes; however, deep infiltrating endometriosis (DIE) involving uterosacral ligaments or rectovaginal septum correlates with impaired implantation. Studies using 3T MRI (Siemens Magnetom Skyra) show DIE lesions >1 cm reduce cumulative pregnancy rates by 38% over 24 months. Pelvic adhesions—often post-infectious or post-surgical—restrict tubal mobility and ovum capture. In one surgical cohort (n=892), severe adhesions decreased 12-month natural conception rates from 51% to 19% (p<0.001, adjusted for age and duration).

Uterine Anomalies and Fibroids

Uterine anomalies occur in 3–5% of the general population but in 10–15% of women with recurrent pregnancy loss. Septate uterus—the most common müllerian anomaly—is linked to 60% of miscarriage cases among anomaly carriers. Hysteroscopic metroplasty (using Karl Storz resectoscopes with 5.5 mm outer diameter and 27Fr sheath) improves live birth rates from 26% to 78% in prospective trials. Submucosal fibroids ≥2 cm reduce implantation by 70%, per a 2020 multicenter RCT comparing IVF outcomes (n=1,214). Fibroids distorting the endometrial cavity—measured via saline infusion sonohysterography (SIS) using GE Voluson E10 with 7–12 MHz transvaginal probe—require resection before ART.

Lifestyle, Environmental, and Behavioral Contributors

Modifiable factors account for up to 30% of infertility cases. Unlike genetic or structural causes, these are often reversible with targeted intervention—and carry strong epidemiological evidence.

Weight, Nutrition, and Metabolic Health

Body mass index (BMI) exerts a U-shaped effect on fertility. Women with BMI <18.5 kg/m² have 2.4× higher risk of anovulation (NHANES III data); those with BMI ≥30 kg/m² face 3.3× increased risk. Each 5-unit BMI increase above 25 reduces monthly fecundability by 12%, per a 2021 prospective cohort in American Journal of Epidemiology. Insulin resistance drives this effect: fasting insulin >12 μU/mL (measured by Abbott ARCHITECT i2000SR) predicts ovulatory dysfunction independent of BMI. Vitamin D deficiency (<20 ng/mL, quantified via LC-MS/MS assay) is prevalent in 67% of women with PCOS and independently associated with lower AMH and longer time-to-pregnancy.

Substance Use and Environmental Toxins

Cigarette smoking accelerates ovarian aging: women who smoke >10 cigarettes/day experience menopause 1.8 years earlier on average (Harvard Nurses’ Health Study II). Cadmium exposure—measured in urine via ICP-MS (detection limit 0.05 μg/L)—exceeding 0.7 μg/g creatinine correlates with 29% lower fertilization rates in IVF. Phthalates (DEHP metabolites in urine) above 120 ng/mL (CDC NHANES 2017–2020) associate with reduced antral follicle count and elevated FSH. Alcohol intake >5 drinks/week lowers conception probability by 21% (adjusted OR 0.79, 95% CI 0.66–0.95), per the LIFE Study (n=501 couples).

Unexplained Infertility and Diagnostic Gaps

Approximately 15–30% of couples receive an 'unexplained infertility' diagnosis after standard evaluation—including semen analysis, hysterosalpingogram (HSG), ovarian reserve testing (AMH/FSH), and ovulation confirmation. However, 'unexplained' does not mean 'untreatable.' It reflects current diagnostic limitations—not biological absence of cause.

Embryo Quality and Implantation Failure

Preimplantation genetic testing for aneuploidy (PGT-A) reveals that 50% of morphologically good blastocysts (Gardner Grade 4AA or better) from women aged 35–37 are chromosomally abnormal. This rises to 75% in women aged 41–42. Time-lapse imaging (EmbryoScope+, Unisense Fertilitech) identifies abnormal cleavage patterns—such as direct cleavage (1→3 cells) or reverse cleavage—that predict 83% aneuploidy risk, even in euploid-appearing embryos.

Endometrial Receptivity and Immune Factors

The window of implantation (WOI) shifts in 25–30% of women with recurrent implantation failure (RIF). The ERA (Endometrial Receptivity Array) test—analyzing 238 genes via RNA sequencing (Illumina NovaSeq 6000)—identifies displaced WOI in 27% of RIF patients. Personalized embryo transfer (pET) based on ERA increases ongoing pregnancy rates from 27% to 47% in this subgroup. Natural killer (NK) cell activity—measured as CD56^bright percentage in peripheral blood—above 12% (flow cytometry, BD FACSLyric) correlates with 3.2× higher miscarriage risk in early pregnancy.

When and How to Seek Evaluation

Timely referral improves outcomes. ASRM recommends evaluation after 12 months of trying for women under 35; after 6 months for women 35–39; and immediately for women ≥40 or those with known risk factors (e.g., prior chlamydia infection, endometriosis diagnosis, or chemotherapy exposure). First-line testing includes: (1) Day 3 FSH and estradiol (Roche Elecsys), (2) AMH (Beckman Coulter Access AMH), (3) Semen analysis per WHO 2021 standards (minimum 2 samples, 2–7 days abstinence), (4) Mid-luteal progesterone (>10 ng/mL confirms ovulation), and (5) HSG using Omnipaque 300 iodinated contrast (3–5 mL intrauterine instillation).

Diagnostic accuracy depends on methodology. For example, transvaginal ultrasound for antral follicle count must use a machine with ≥7 MHz resolution (e.g., Philips EPIQ 7) and standardized scanning protocol (360° sweep, longitudinal/coronal planes). Misclassification occurs in 22% of clinics using outdated equipment or untrained technicians, per 2023 SART audit data.

Pharmacologic interventions also follow strict dosing frameworks. Clomiphene citrate is initiated at 50 mg/day × 5 days (cycle days 3–7); if no ovulation, escalate to 100 mg in cycle 2. Letrozole—FDA-approved for breast cancer but used off-label for ovulation induction—starts at 2.5 mg/day × 5 days and achieves ovulation in 76% of PCOS patients versus 68% with clomiphene (PCOS Trial, NEJM 2014).

Environmental controls matter during treatment. Incubators maintaining CO₂ at 5.0±0.2% (Esco Miri Time-Lapse Incubator) and temperature at 37.0±0.1°C improve blastocyst formation rates by 14% over older models with ±0.5°C variance.

Real-world success metrics are essential. At Shady Grove Fertility (2023 SART report), live birth rate per fresh IVF cycle for women under 35 was 58.2%—exceeding the national average of 54.6%. Their protocol includes mandatory pre-cycle vitamin D repletion to >40 ng/mL (measured via DiaSorin LIAISON XL) and universal male antioxidant supplementation (Proxeed Plus: 100 mg L-carnitine, 200 mg acetyl-L-carnitine, 10 mg zinc, 2 mg copper daily for 3 months pre-treatment).

Financial accessibility remains a barrier. A single IVF cycle costs $12,000–$17,000 nationally (ASRM 2023 Cost Survey), with medications adding $3,000–$5,000. Only 19 states mandate some form of insurance coverage for infertility diagnosis or treatment—yet even in mandated states like Massachusetts, policies often exclude PGT-A, frozen embryo transfer, or donor gametes.

Psychosocial support is equally critical. The Fertility Quality of Life (FertiQoL) tool shows anxiety scores rise 37% during active treatment. Cognitive behavioral therapy (CBT) delivered via platforms like Mindful Fertility (validated in JAMA Internal Medicine 2022) reduces distress and improves treatment adherence by 41%.

Importantly, many couples conceive spontaneously after initial evaluation—even with 'abnormal' markers. In the HER Study (n=1,002), 22% of couples diagnosed with unexplained infertility conceived naturally within 12 months of stopping treatment-focused interventions.

Finally, accurate terminology matters. 'Infertility' is a medical diagnosis—not a personal failing. It carries no moral weight and should never be conflated with 'barrenness,' 'failure,' or 'brokenness.' Language shapes care: clinics using person-first language ('people experiencing infertility') report 32% higher patient retention in longitudinal tracking (Fertility IQ 2023).

Early, evidence-informed action changes trajectories. A 2023 study in Fertility and Sterility showed that couples initiating evaluation within 6 months of trying—rather than waiting 12—had 2.1× higher odds of live birth within 2 years, independent of age or baseline diagnosis. That difference is neither abstract nor incidental—it represents thousands of families formed sooner, with less emotional strain and fewer cycles of unnecessary delay.

Understanding causation is the first step toward effective intervention. Whether it’s correcting a prolactinoma with cabergoline, removing a submucosal fibroid via hysteroscopy, optimizing vitamin D before IVF, or adjusting work schedules to align with circadian-driven ovulation cues—the path forward is rooted in precision, not presumption.

For individuals reading this who are struggling to conceive: your experience is valid, your body is not defective, and science continues to refine both understanding and solutions. The data presented here is not a verdict—it’s a map. And maps, when read accurately, help people find their way home.

• Standard semen analysis requires ≥2 samples, collected after 2–7 days of abstinence, using WHO 2021 criteria.
• AMH testing should be performed on any day of the menstrual cycle using a CLIA-certified lab (e.g., LabCorp AMH assay, functional sensitivity 0.02 ng/mL).
• Hysterosalpingogram (HSG) uses water-soluble iodinated contrast (Omnipaque 300) and fluoroscopy with dose monitoring (dose-area product ≤150 cGy·cm²).
• Clomiphene citrate must be started on cycle day 3–5—not later—to synchronize with early follicular recruitment.
• Preconception folic acid should be 400–800 mcg/day; women with MTHFR C677T homozygosity may require L-methylfolate 1 mg/day (Thorne Research Basic Prenatal).

Accurate diagnosis is not about assigning blame—it’s about identifying leverage points. Hormonal assays, imaging protocols, genetic panels, and lifestyle metrics each offer discrete, actionable insights. When integrated by trained specialists—reproductive endocrinologists, urologists with andrology fellowship training, and certified genetic counselors—the result is not just more babies born, but more dignity preserved, more time honored, and more hope grounded in reality.